Testosterone Therapy for Women: What the Evidence Supports

Testosterone therapy for women has one evidence-based indication, and it is narrower than most of the internet suggests. A global consensus of endocrine and menopause societies concluded that the only such indication is hypoactive sexual desire disorder in postmenopausal women — and that the evidence does not support using testosterone for energy, mood, cognition, or bone health in women.[1] There is also no testosterone product approved anywhere specifically for female use.

That is a narrow answer, and it is the honest one. Everything below explains what sits behind it.

Women produce testosterone, and it declines with age

Testosterone is not a male-only hormone. Women produce it in the ovaries and adrenal glands, and across a woman's reproductive years it circulates at concentrations substantially higher than estradiol by mass.

Levels fall gradually with age. Importantly, the decline is age-related rather than something menopause itself causes — natural menopause does not produce the abrupt drop that many people expect. Surgical removal of the ovaries is different: it causes a sudden, substantial fall in circulating testosterone.

The one indication the evidence supports

In 2019, an international panel spanning endocrine, menopause, and sexual medicine societies published a consensus position statement. Its central conclusion: the only evidence-based indication for testosterone in women is treatment of hypoactive sexual desire disorder — persistent, distressing low sexual desire — in postmenopausal women, following a full clinical assessment.[1]

The supporting evidence is substantial. A systematic review and meta-analysis of 36 randomized controlled trials covering 8,480 women found that testosterone significantly improved sexual function compared with placebo: an increase of 0.85 satisfying sexual events per month (95% CI 0.52–1.18) and a standardized mean difference of 0.36 for sexual desire (95% CI 0.22–0.50), alongside improvements in arousal, orgasm, pleasure, and sexual self-image, and reductions in sexual distress.[2]

Those are real, replicated effects. They are also moderate rather than dramatic — roughly one additional satisfying sexual event per month is the honest way to describe the headline number.

What the evidence does not support

This is where most marketing departs from the science. The consensus statement found insufficient evidence to support testosterone therapy in women for cognition, general wellbeing, bone health, or any indication other than HSDD.[1]

If you have encountered testosterone marketed to women for fatigue, brain fog, mood, muscle, or "hormone optimization" generally, that use is not supported by the trial evidence. It may still be prescribed — but it is being prescribed ahead of the evidence, not because of it.

No approved product, and what that means in practice

There is currently no testosterone formulation approved specifically for women. The consensus panel described this as an unmet need and called for female-specific products to be developed and approved.[1]

In practice, treatment means off-label use of male formulations at reduced doses, with monitoring to keep blood concentrations within the normal premenopausal female range. Two things follow from that:

Route matters. The meta-analysis found that oral testosterone raised LDL cholesterol and lowered HDL cholesterol and triglycerides, while non-oral routes — transdermal patch or cream — had a neutral effect on lipids. Non-oral delivery is preferred on that basis.[2]

Some formulations are explicitly discouraged. The consensus statement recommends against formulations that produce supraphysiological concentrations, naming pellets and injections specifically.[1] The therapeutic target is a normal premenopausal level, not a high one.

Safety, stated accurately

In the pooled trial data, no serious adverse events were recorded. The side effects that did appear were increased weight, and a greater likelihood of acne and unwanted hair growth.[2] Short-term transdermal therapy has not been shown to affect breast cancer risk.

The important caveat is duration. Safety data for testosterone at physiological doses in women do not extend beyond 24 months of treatment.[1] Trials also excluded higher-risk populations, which limits how far their safety findings generalize. Anyone considering long-term therapy is going beyond the evidence base, and should know that.

Frequently asked questions

Can testosterone help with fatigue or brain fog in women? The evidence does not support it. The consensus review found insufficient evidence for testosterone in women for cognition, wellbeing, or indications other than HSDD.[1] Persistent fatigue or cognitive symptoms deserve a workup — thyroid, iron, sleep, mood — rather than a hormone prescribed off the evidence.

Is there a blood test for low testosterone in women? There is no established testosterone threshold that defines deficiency in women, which is why the consensus recommends diagnosis based on clinical assessment rather than a lab cutoff. Blood levels are used to confirm therapy stays within the premenopausal physiological range, not to make the diagnosis.[1]

Is testosterone safe for women long term? Unknown. Safety at physiological doses has not been established beyond 24 months.[1] That is a genuine gap in the evidence rather than a reassurance.

Why is there no approved product for women? Female-specific formulations have not been brought through approval, so treatment relies on dose-adjusted male products. The consensus panel identified this explicitly as an unmet need.[1]

Where this leaves you

If you are postmenopausal with persistently low sexual desire that causes you distress, testosterone is a legitimate, evidence-supported option worth discussing with a clinician — with realistic expectations about effect size and an honest acknowledgment of the long-term safety gap.

If you are being offered testosterone for energy, mood, weight, or general optimization, the evidence does not currently support that use, and it is reasonable to ask what it is based on.

Keen connects you with licensed clinical providers for telehealth consultation and lab review.

The numbers behind this

The effect sizes underneath the position above — 36 randomised trials, 8,480 women, domain by domain, plus the lipid finding that decides the route — are set out in what testosterone does for women's sexual function.

References

2 sources

1. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660–4666. doi:10.1210/jc.2019-01603 · PMID 31498871
2. Islam RM, Bell RJ, Green S, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754–766. doi:10.1016/S2213-8587(19)30189-5 · PMID 31353194